Poor health-related quality of life despite Lupus Low Disease Activity State or Definitions of Remission in systemic lupus erythematosus (SLE) remission in patients with SLE: results from a clinical trial setting.

ABSTRACT:

Objective

To determine the prevalence of poor health-related quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE) in Lupus Low Disease Activity State (LLDAS) or Definitions of Remission in SLE (DORIS) remission and sustained LLDAS or sustained DORIS remission, after a 52-week therapeutic intervention.

Methods

We analysed data from four phase III trials of belimumab in SLE (BLISS-52, BLISS-76, BLISS-SC, EMBRACE; n=2406). Sustained LLDAS/remission was defined as persistent LLDAS/remission for at least two visits, maintained through week 52. Poor HRQoL was defined as Short Form-36 (SF-36) physical/mental component summary (PCS/MCS) and domain scores ≤the normative fifth percentile, Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) score

SUBMITTER: Parodis I 

PROVIDER: S-EPMC12581079 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature